OncoSec Medical Inc (NASDAQ:ONCS) shares were up 13% during mid-day trading on Monday . The stock traded as high as $2.30 and last traded at $2.09, approximately 547,903 shares traded hands during mid-day trading. An increase of 506% from the average daily volume of 90,359 shares. The stock had previously closed at $1.85.
Several equities analysts have recently issued reports on ONCS shares. Zacks Investment Research raised shares of OncoSec Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, December 31st. Maxim Group set a $6.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a research note on Thursday, October 10th.
The firm’s 50-day moving average price is $1.94 and its two-hundred day moving average price is $2.06. The company has a quick ratio of 2.79, a current ratio of 2.79 and a debt-to-equity ratio of 0.04.
Several institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC purchased a new position in shares of OncoSec Medical in the second quarter worth approximately $27,000. Citadel Advisors LLC purchased a new position in shares of OncoSec Medical in the second quarter worth approximately $33,000. Salzhauer Michael purchased a new position in shares of OncoSec Medical in the third quarter worth approximately $28,000. JPMorgan Chase & Co. purchased a new position in shares of OncoSec Medical in the second quarter worth approximately $46,000. Finally, D.A. Davidson & CO. purchased a new position in shares of OncoSec Medical in the third quarter worth approximately $47,000. 7.17% of the stock is currently owned by institutional investors and hedge funds.
OncoSec Medical Company Profile (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Featured Story: Book Value Per Share – BVPS
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.